Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...
Non-alcoholic fatty liver disease is on the rise and mainly stems from metabolic dysfunction. Dr Sood shares five facts about ...
On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe liver ...
GAITHERSBURG, Md., June 05, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and ...
Fatty liver disease sounds mild, almost harmless. That name alone pushes many people into denial. There is usually no pain, no dramatic symptom, and no daily disruption. So the condition stays ...
ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results